Discovery Park International

Lilly, Chao Center, PDA Partner With Russian Officials to Improve Quality of Global Drug Manufacturi

August 6, 2009

"Common global standards in pharmaceutical manufacturing are in the best
interests of public health and patient safety," said Frank Deane, Ph.D.,
president of manufacturing operations at Lilly. "Partnering with regulatory
agencies and manufacturers is an important step toward achieving these
standards."

Fionnuala Walsh, Ph.D., vice president of quality at Lilly, said sharing best
practices with Russia and other countries not only supports meeting this
challenge but also helps Lilly, the Chao Center and the PDA fine-tune their own
training practices.

"One of the global challenges that pharmaceutical companies face is ensuring the
quality and integrity of medicines that are manufactured and distributed in
different countries," Walsh said.

The Chao Center manufactures and distributes Seromycin, which treats
multidrug-resistant tuberculosis. The drug was developed by Lilly.

"An important mission of the Chao Center is to teach future pharmaceutical
scientists and drug manufacturers the production and distribution of
late-lifecycle drugs," said Joseph B. Hornett, senior vice president, treasurer
and COO of the Purdue Research Foundation, which manages the Chao Center. "We
can take what we learn from our partnership with the Russian Inspectorate and
incorporate it into our own training and educational programs."

Officials from the Russian Inspectorate and Rozdravnadzor will participate in
training in manufacturing simulation facilities at Lilly and the Chao Center in
Indiana, as well as the PDA in Bethesda, Md., in the coming months, said Hugh
Sutherland, director of manufacturing and quality training and development at
Lilly.


Eli Lilly and Company corporate communications
Ed Sagebiel, 317-433-9899
egs@lilly.com
or
Purdue Research Foundation
Cynthia Sequin, 765-588-3340
casequin@prf.org

Bookmark and Share

More Information

View All News...